Therapeutic hypothermia in asphyxiated newborns: selective head cooling vs. whole body cooling — comparison of short term outcomes

Ewa Matylda Gulczynska1, Janusz Gadzinowski2, Marcin Kesiak1, Barbara Sobolewska1, Joanna Caputa2, Anna Maczko3, Wojciech Walas3, Wioletta Cedrowska-Adamus1, Tomasz Talar3

1Department of Neonatology, Polish Mother Memorial Hospital — Research Institute, Lodz, Poland
2Department of Neonatology, Poznan University of Medical Sciences, Poznan, Polska
3Pediatric Intensive Care Unit, University Hospital in Opole, Poland

ABSTRACT
Objectives: Therapeutic hypothermia TH became broadly used in the management of the asphyxiated newborns. Although two cooling methods are used, so far the superiority of none of them has been established. The purpose of the study is to compare two cooling methods: selective head cooling (SHC) and whole body cooling (WBC).

Material and methods: We conducted a prospective observational study in newborns with HIE. The patients received one of methods: SHC or WBC. The eligibility criteria were similar to previous studies. Stability of cardio-respiratory parameters and short term outcomes were analyzed.

Results: 78 neonates with hypoxic-ischemic encephalopathy due to perinatal asphyxia were involved in this study. The SHC group consisted of 51 newborns, the WBC group consisted of 27 patients. Both study groups had similar baseline characteristics and condition at birth. There were no significant differences in hospital course, neurological status and adverse effects associated with cooling procedure between groups. Analyzing the rate of thrombocytopenia and the number of transfusions of blood components no statistically significant differences were found between the groups.

Conclusions: Results of our study indicate that two compared methods of TH despite varied target core temperature ranges do not differ significantly according to clinical course and risk of adverse events. Further observations are conducted and we look forward to the results of the long neurodevelopmental care.

Key words: asphyxia; hypoxic–ischemic encephalopathy; newborn; selective head cooling; whole-body cooling

INTRODUCTION
Despite the advances in perinatal care, asphyxia of neonates remains a serious condition leading to significant mortality and morbidity. According to WHO about 2.6 million of deaths occur annually in the neonatal period. Perinatal asphyxia represents the third most common cause of neonatal death (23%) after preterm birth (28%) and severe infections (26%). It means that all over the world, almost 600 000 newborns die every year and at least the same number develop severe consequences such as epilepsy, cerebral palsy and developmental delay due to acute perinatal sentinel events [1].

In the 90s of the last century, it was confirmed that the decline in brain temperature by 2°C to 5°C provided neuroprotection [2–4]. Encouraging results of the first applications of therapeutic hypothermia in human neonates enabled to construct prospective randomized trials, initially with a control (not cooled) group of asphyxiated newborns. Research results, since the pioneering studies [5, 6] through the multicenter trials, were convincing and led to immediate acceptance of medical devices for TH by the FDA [7–12]. The outcomes of RCT studies confirmed the lower mortality rates and improvement of neurodevelopmental outcomes in cooled neonates. Current guidelines for neonatal resuscitation (since 2010) recommend the use of therapeutic hypothermia as a standard treatment in newborns with moderate or severe hypoxic-ischemic encephalopathy.

The Olympic Cool-Cap providing selective head cooling with mild systemic hypothermia was the first method of cooling approved by FDA in 2006 to be used in newborns with HIE.
Subsequently, in 2010 Tecotherm Neo device — Inspiration was introduced into the European market and at the same time (2010 and 2014) Arctic Sun TMS and Blanketrol AE; received the acceptance of the FDA. Apart from the Cool-Cap all the other devices mentioned above were dedicated to the second method of hypothermia: whole body cooling (WBC). The indications for hypothermia include: an acute hypoxia incident, Apgar score ≤ 5 in 10 min, resuscitation for 10 min after birth or severe acidosis (pH < 7 or BE > 16 mmol/L) (in umbilical cord blood or in the first 60 min after birth), neurological symptoms of moderate or severe hypoxic-ischemic encephalopathy and pathological aEEG recording [13]. Because of a very short therapeutic window after perinatal sentinel events the treatment with TH should be started in the first 6 hours of life and continued for 72 hours. The inclusion criteria also contain: the maturity above 36 weeks of pregnancy and birth body weight > 1800 g. Although whole body cooling is now more popular and more commonly exploited, both methods are used and considered as appropriate and equivalent [14]. So far we have only a few studies comparing the two aforementioned methods of therapeutic hypothermia of newborns [15]. The superiority of either, SBC or WBC, has not been established.

MATERIAL AND METHODS

The prospective observational study was carried out in three centers. Two NICUs at level III perinatal centers and one Pediatric Intensive Care Unit participated in this study. The inclusion criteria were consistent with earlier randomized control trials: post menstrual age ≥ 36 weeks, Apgar ≤ 5 at 10 minutes of life and umbilical cord blood pH < 7.1 and/or base excess (BE) ≥ 16 mmol/L, respiratory support until 10th minute of life. The exclusion criteria involved: major congenital malformations, life-threatening abnormalities and extremely poor prognosis (i.e. Apgar score 0 for longer than 10 minutes of life). Subsequently, all the considered infants were neurologically examined according to Sarnat classification [16]. Newborns with clinical symptoms of moderate or severe HIE were further assessed with integrated EEG by means of infant electroencephalography Monitor Olympic CFM™ 6000, Natus Medical, USA. Moderately or severely abnormal aEEG traces were the entry criteria for therapeutic hypothermia. The selection of the cooling method, either WBC or SHC, depended on the cooling equipment available at the time in the care unit. The study protocol received the ethics approval of the bioethical board — PMMH — Research Institute Ethical Committee. Informed consent was obtained from all the legally designated representatives of the study neonates.

Therapeutic hypothermia protocol

Therapeutic hypothermia was initiated in the first 6 hours of life and continued for 72 hours. The cooling period was followed by a rewarming phase and the rewarming speed was set at 0.5°C per hour. Throughout the course of the cooling and rewarming process, vital signs (heart rate, arterial blood pressure, rectal temperature) and parameters of respiratory support (FiO2, MAP, level of respiratory support) were monitored and recorded every hour for the first 6 hours, then every three hours, and again every hour during the rewarming. A total of 36 measurements were taken. The vital signs were monitored using Philips IntelliVue MP70 Neonatal Monitors or Drager Infinity® Delta Monitors.

The use of medicines like: vasopressors, anticonvulsants, steroids, volume expanders and inhaled nitric oxide were recorded. Parameters of coagulation were followed closely and the number of blood components transfusions (platelets, fresh frozen plasma, red blood cells) during the first 7 days of life were noted. Additionally, clinical data such as the number of seizure episodes, the incidence of IVH detected by cranial USG, the rate of PPHN confirmed by ECHO exam and feeding difficulties were analyzed. The assessment of the neurological status of the studied infants was carried out daily by trained personnel using the Thompson Encephalopathy Score [17].

Statistical analysis

In order to compare the percent accuracy between groups Chi-square or Fisher exact test were applied. One-way or two-way analysis of variance (ANOVA) was used for continuous data to investigate the differences between groups and changes observed over time. Fishers LSD (least significant difference) post hoc comparison tests were used to identify any significant differences between mean values. Differences in the means of the ranks of the values between groups were analyzed with the Student’s t-test or Mann-Whitney U test. Statistical analysis was carried out using STATISTICA (StatSoft, Tulsa, OK, USA, version 6.0 PL). Statistical significance was assumed at p-value < 0.05.

RESULTS

Seventy nine neonates were included in this study. The SHC group consisted of 51 newborns, the WBC group was composed of 27 patients. Table 1 shows demographic and clinical data of the study population.

Groups had similar baseline characteristics and condition at birth. pH, BE values in umbilical cord blood, rectal temperature at admission and neurological assessment on the initiation of the cooling procedure were also similar between the groups. The majority of the analysed patients: 21 out of 27 (77.8%) of patients in WBC and 42 out of 51 (82.4 %) patients in the SHC were outborn so neonatal interfacility transport was used. Emergency C-section procedure rates did not differ between groups: 74.1% vs. 69.8%. Therapeutic hypothermia initiation time equaled...
The rectal temperature evidently varied between the groups: during the maintenance phase of hypothermia the average temperature in the WBC group was 33.5°C whereas in the SHC it amounted to 34.2°C (p-value 0.000). During the rewarming phase the differences gradually decreased reaching normothermia (Fig. 1).

Table 1. Demographic data and clinical characteristics of the study subjects

<table>
<thead>
<tr>
<th></th>
<th>SHC 51</th>
<th>WBC 27</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Postmenstrual age [weeks]; mean (± SD)</td>
<td>38.53 (± 1.7)</td>
<td>38.96 (± 1.9)</td>
<td>0.71</td>
</tr>
<tr>
<td>Female gender, number (%)</td>
<td>23 (43.4)</td>
<td>19 (70.3)</td>
<td>0.33</td>
</tr>
<tr>
<td>Birth body weight [g]; mean (±SD)</td>
<td>3213.6 (762.2)</td>
<td>3276.9 (625.7)</td>
<td>0.31</td>
</tr>
<tr>
<td>Cesarean delivery (%)</td>
<td>37 (69.8)</td>
<td>20 (74.1)</td>
<td>0.69</td>
</tr>
<tr>
<td>Apgar score: @ 5 minutes; @10 minutes,</td>
<td>2.84 (± 1.71) 3.54 (± 1.70)</td>
<td>2.11 (± 1.89) 2.92 (± 1.87)</td>
<td>0.08</td>
</tr>
<tr>
<td>Umbilical blood pH* (± SD)</td>
<td>6.89 (0.151)</td>
<td>6.87 (0.184)</td>
<td>0.62</td>
</tr>
<tr>
<td>Outborns n (%)</td>
<td>42 (82.4)</td>
<td>21 (77.8)</td>
<td>0.63</td>
</tr>
<tr>
<td>Base excess (BE)*</td>
<td>-19.92 (± 4.8)</td>
<td>-19.78 (± 4.8)</td>
<td>0.92</td>
</tr>
<tr>
<td>Rectal temperature at admission [°C]</td>
<td>33.8 (± 1.81)</td>
<td>33.7 (± 1.63)</td>
<td>0.86</td>
</tr>
<tr>
<td>HIES (Thompson scale) at &lt; 6 hrs of age</td>
<td>10.36</td>
<td>11.06</td>
<td>0.49</td>
</tr>
<tr>
<td>7th day of life</td>
<td>1.87</td>
<td>2.66</td>
<td>0.75</td>
</tr>
<tr>
<td>Neonatal seizures prior to cooling (n; %)</td>
<td>26 (51.0)</td>
<td>7 (26.9)</td>
<td>0.04</td>
</tr>
<tr>
<td>TH initiation time [minutes of life]</td>
<td>317 (± 167)</td>
<td>357.0 (± 122)</td>
<td>0.08</td>
</tr>
</tbody>
</table>

The difference p-value of < 0.05 was considered statistically significant.

*the worst values: umbilical cord blood or any blood sampling during the first hour after birth

Figure 1. Time sequence of changes in rectal temperature. The average rectal temperature during the maintenance and re-warming phase (WBC vs. SHC) (mean, ± SD) 357 (± 122) and 317 (± 167) minutes in the WBC and SHC respectively (p-value 0.08).

The rectal temperature evidently varied between the groups: during the maintenance phase of hypothermia the average temperature in the WBC group was 33.5°C whereas in the SHC it amounted to 34.2°C (p-value 0.000). During the rewarming phase the differences gradually decreased reaching normothermia (Fig. 1).

In the WBC group the mean HR values equaled 116.4 (SD ± 21.1) bpm, whereas in the SHC group 114.9 (± 20.1) bpm; (p-value 0.58). A similar observation concerned measurements of the mean arterial blood pressure which amounted to (mean ± SD) 51.1 (± 10.2) mmHg in the WBC group and to 49.4 (± 9.9) in the SHC group, however, a tendency to lower MABP was found in the SHC, (p-value 0.099). Nonetheless, the difference between the groups was not statistically significant. Mean arterial pressure (MAP) in the 36 points of measurement in WBC and SHC groups are shown in Figure 2. Time 0 in these and subsequent figures designates the initiation of the cooling procedure.
The analysis of the frequency of inotropes use did not reveal significant changes. Additionally, the mean number of days of inotropes administration calculated on the number of people in the group was not statistically significant (Tab. 2).

When analyzing the course of hospitalization and the rate of complications, no differences were found. The respiratory support and oxygen supplementation time were not significantly different. However, the rate of neonates who required any respiratory support (MV or noninvasive support) between 36–80 hour of cooling was significantly higher in the WBC vs. SHC group, 83.6% vs. 72% respectively; (p-value 0.047). During the whole therapeutic hypothermia procedure the fraction of inspired oxygen (p-value 0.99) and mean airway pressure (p-value 0.68) did not differ between the groups.

The rate of PPHN decreased and the need for inhaled nitric oxide (INO) was reduced three-fold in the SHC group but the rate of its incidence was very low. The average platelets count in all controlled tests was similar in both groups. In the WBC group a statistically significant decrease in mean PLTs values was observed on the 2\textsuperscript{nd}, 3\textsuperscript{rd} and 4\textsuperscript{th} days compared to baseline values in the first 24 hours. The reduction in the following days reached 38% of the initial value. A smaller reduction in average platelets values was observed in the SHC group, by only 21%. The incidence of

![Table 2. Hospital Course and Status at Discharge. Analysis of drug and blood components administration in the first week of life](image-url)

<table>
<thead>
<tr>
<th></th>
<th>SHC 51</th>
<th>WBC 27</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Respiratory support No [%] mean [days] (± SD)(a)</td>
<td>4.8 (± 3.6)</td>
<td>6.0 (± 6.6)</td>
<td>0.37</td>
</tr>
<tr>
<td>Noninvasive support [days] mean (± SD)(aa)</td>
<td>0.7 (± 1.3)</td>
<td>1.5 (± 3.6)</td>
<td>0.26</td>
</tr>
<tr>
<td>Oxygen therapy [days] mean (± SD)</td>
<td>5.6 (± 7.6)</td>
<td>4.5 (± 3.8)</td>
<td>0.47</td>
</tr>
<tr>
<td>Diagnosis of PPHN Administration of inhaled NO (INO)</td>
<td>6 (11.3) 2 (3.8)</td>
<td>5 (18.5) 4 (14.8)</td>
<td>0.38 0.08</td>
</tr>
<tr>
<td>Thrombocytopenia 100 000/microliter (μL) Number, [%]</td>
<td>23 45.1</td>
<td>12 45.1</td>
<td>0.93</td>
</tr>
<tr>
<td>RBC transfusion (No; No of patients) No/patient</td>
<td>10/6 0.2</td>
<td>7/5 0.28</td>
<td>0.46</td>
</tr>
<tr>
<td>FFP transfusion (No; No of patients) No/all patients</td>
<td>20/12 0.39</td>
<td>24/13 0.89</td>
<td>0.36</td>
</tr>
<tr>
<td>PLT transfusion (No; No of patients) No/patient</td>
<td>5/5 0.1</td>
<td>4/3 0.16</td>
<td>0.30</td>
</tr>
<tr>
<td>Catecholamine use: none 1 ≥ 2</td>
<td>18 (35.3%) 19 (31.4%) 17 (33.3%) 3.14</td>
<td>12 (44.4%) 1 (3.7%) 14 (51.8%) 4.04</td>
<td>0.08 0.19</td>
</tr>
<tr>
<td>Volume replacement therapy (No; No of patients) No/patient</td>
<td>5/5 0.2</td>
<td>13/9 0.25</td>
<td>0.20</td>
</tr>
<tr>
<td>Anticonvulsant administration (No of patients) No of doses/all patients</td>
<td>40 141/2.8</td>
<td>24 80/2.9</td>
<td>0.94</td>
</tr>
<tr>
<td>Antibiotic therapy [days] mean (±SD)</td>
<td>14.5 (± 7.6)</td>
<td>13.1 (± 6.8)</td>
<td>0.43</td>
</tr>
<tr>
<td>Full enteral feeding Oral feedings (sucking) (days) mean (± SD)</td>
<td>14.5 (± 5.9) 16.7 (± 10.2)</td>
<td>14.7 (± 5.1) 14.3 (± 5.4)</td>
<td>0.92 0.37</td>
</tr>
<tr>
<td>Age at discharge/DOL mean (± SD)</td>
<td>27.26 (± 13.0)</td>
<td>21.91 (± 11.3)</td>
<td>0.09</td>
</tr>
<tr>
<td>Death during hospital stay n (%)</td>
<td>3 (6.0) 28.3</td>
<td>2 (8.3)</td>
<td>0.71</td>
</tr>
</tbody>
</table>

\[a\]any type of mechanical ventilation (SIMV, PC, HFOV)

\[aa\]any type of noninvasive respiratory support (noninvasive ventilation, nasal CPAP)

The p-value of < 0.05 was considered statistically significant

The analysis of the frequency of inotropes use did not reveal significant changes. Additionally, the mean number of days of inotropes administration calculated on the number of people in the group was not statistically significant (Tab. 2)

When analyzing the course of hospitalization and the rate of complications, no differences were found. The respiratory support and oxygen supplementation time were not significantly different. However, the rate of neonates who required any respiratory support (MV or noninvasive support) between 36–80 hour of cooling was significantly higher in the WBC vs. SHC group, 83.6% vs. 72% respectively; (p-value 0.047). During the whole therapeutic hypothermia procedure the fraction of inspired oxygen (p-value 0.99) and mean airway pressure (p-value 0.68) did not differ between the groups.

The rate of PPHN decreased and the need for inhaled nitric oxide (INO) was reduced three-fold in the SHC group but the rate of its incidence was very low. The average platelets count in all controlled tests was similar in both groups. In the WBC group a statistically significant decrease in mean PLTs values was observed on the 2\textsuperscript{nd}, 3\textsuperscript{rd} and 4\textsuperscript{th} days compared to baseline values in the first 24 hours. The reduction in the following days reached 38% of the initial value. A smaller reduction in average platelets values was observed in the SHC group, by only 21%. The incidence of
thrombocytopenia 100 x 10^9/L found in each of the groups did not differ statistically significantly; (p-value 0.93). Also, the number of transfusions of different blood components (fresh frozen plasma, erythrocytes and platelets) did not differ significantly (Tab. 2).

Results of neonatal neurological status assessment performed daily according to Thompson scale are presented in Figure 3. On the following days of the treatment, to the fifth day of study (after the hypothermia was completed), the score was comparable in both groups. The rate of neurological status improvement expressed as a percentage decrease in Thompson scores was slightly better in SHC i.e. by 83.1% vs. 74.3% in WBC group in comparison with initial values.

**DISCUSSION**

Currently, therapeutic hypothermia is a standard treatment of hypoxic-ischemic encephalopathy in neonates [18]. The SHC was the first method of therapeutic hypothermia utilized in the neonatal period. The only device is a system utilizing a special cooling cap to provide selective brain cooling while maintaining core temperature at safe levels through the use of a radiant warmer. The Cool-Cap works by maintaining a steady flow of cool water at a selected temperature through a plastic cap covering the infant’s head. The temperature is manually controlled. In this way the newborn’s brain is the coldest part of the body. The rectal temperature is maintained at the level of 34.0–35.0°C. Nowadays, the whole body cooling method is slightly lower and maintained at the level of 33.5 ± 0.5°C. Nowadays, the whole body cooling method seems more popular and more often used. However, both methods are used as before and considered equivalent in terms of effectiveness. Because the target ranges of deep body temperature are different, many users pose a question of the side effects as well as the effectiveness of both methods. In the animal model (piglet), which has a much smaller head compared with the human newborn infant, using SHC it was possible to cool the basal ganglia to the temperature lower by 5°C than rectal temperature [18], however, in adults, a considerable temperature gradient between the surface of the head and deep brain structures, where the temperature is similar to rectal temperature (Trec), was observed. Therefore, deep brain temperature remains almost equal to core temperature even when extreme cold is applied to the surface of the head [19]. It seems possible that the temperature gradient between head surface and deep brain structure could be substantial and may have an influence on regional brain temperature. Theoretically, it is possible that fluctuations in Trec and, in consequence, brain temperature may adversely affect the neuroprotective effect of TH. There is evidence that brain temperature is an important factor in regulating BBB permeability, alterations in brain water homeostasis and subsequent structural abnormalities of brain cells [20]. So far, we have only a few studies comparing the two methods of therapeutic hypothermia employed in neonatal period [15].

As expected, in our studied group differences in Trec were observed. The mean Trec in WBC group was 33.5°C and was the same as noticed in TOBY trial [21]. In the SHC group mean Trec was only 34.2°C, which means that the differences were smaller than expected and amounted only to 0.66°C. It may express the tendency of the medical team to maintain a target temperature in the lower ranges in manually controlled devices. The stability of vital parameters: mean target Trec, ABP, and HR at hourly intervals were previously assessed by Hoque et al. [22]. They compared four groups of newborns: 1 group treated with SHC, and 3 groups receiving different variants of WBC. The authors did not find differences in mean ABP or mean HR between groups during the maintenance phase of cooling. They noticed greater variation in Trec in the SHC group during rewarming phase. No other clinical outcomes were analyzed.

Earlier studies have shown the effect of hypothermia on the frequency of inotropic agents used [7]. Meta-analysis of previous RCT (TH vs. control group) assessed cardiovascular effect and revealed increased risk of hypotension treated with inotropes in hypothermia group RR 1.17 (95% CI 1.00, 1.38), RD 0.08 (0.00, 0.17) [23]. In our research, despite the obvious depth temperature measurements (Trec) dif-

Figure 3. The mode of respiratory support in the WBC and SHC groups during the whole TH procedure. Any type of applied mechanical ventilation (SIMV, PC, HFOV) and noninvasive respiratory support (noninvasive ventilation, nasal CPAP) were analyzed jointly.
ferences, we did not notice differences in the mean HR as well as mean ABP between groups. The rate and duration of inotropes administration were also similar. This observation is consistent with reports by other experts [24]. Although the SHC group was cooled using the standardized Cool Cap device, the low-tech method (cooling the baby’s environment using a room air conditioner) was used in the WBC group. No differences in the following clinical parameters: low blood pressure, bradycardia, thrombocytopenia, coagulopathy, renal failure, necessity of respiratory support and discontinuation of mechanical ventilation or PPHN were identified during the cooling and rewarming procedure. Likewise, a non-randomized trial conducted at University of Michigan (WBC-28, SHC-31) confirmed that important components of multi-organ system dysfunction and hypotension treated with inotropes for > 24 h, commonly required in newborns with HIE, were similar for both methods of TH [25, 26].

The requirement for invasive mechanical ventilation, ability to perform extubation during the period of cooling and risk of PPHN were analyzed in two studies [25, 27]. No differences were found between groups in regard to the need of mechanical ventilation during the cooling or ability to be extubated during the cooling. In both analyses the rate of mechanical support while the cooling was being carried out was above 90%. In addition, the possibility of extubation and newborns breathing on their own during the cooling procedure was confirmed (WBC 42.8% vs. SHC 37.9%). The highest values of peak inspiratory pressure (PIP), positive end-expiratory pressure (PEEP), FiO2 (fraction of inspired oxygen), and PaCO2 (partial pressure of carbon dioxide) were investigated during the cooling procedure. No differences were found in the above mentioned respiratory settings between WBC and SHC groups [28]. Our findings are consistent with previous studies. Initially mechanical support was required by 92% of neonates in both groups, but at 72 hours of cooling artificial ventilation was used only in 65.2% SHC vs. 66.6% WBC. As was the case in the literature quoted earlier, we did not observe significant differences between analyzed groups. (Fig. 4, Tab. 2). In all three studies, the PPHN risk was higher in the WBC group but it did not reach statistical significance.

Thrombocytopenia is one of the most frequently reported side-effects of therapeutic hypothermia and its incidence is significantly different and varies from 3–65%. Differences are probably related to definitions of thrombocytopenia and differences in timing of platelet count assessment [28]. Meta-analysis of four trials [5, 6, 19] showed statistically significantly increased thrombocytopenia in the hypothermic groups (RR: 1.55, 95% CI: 1.14, 2.11, NNH: 8, 95% CI: 5, 50) [29]. The next analysis (8 RCT) confirmed a risk of thrombocytopenia in the hypothermia group RR 1.21 (95% CI 1.05–1.40) [23, 30]. The observed difference suggests an additional effect of hypothermia on platelet count in infants with perinatal asphyxia. A slight statistical increase in the risk of thrombocytopenia was detected in the group of infants treated with SHC [23]. In our study the frequency of thrombocytopenia was 32.7% (SHC) vs. 37% (WBC) and no statistical differences were observed. The aforementioned research conducted by Atici did not notice the differences in the risk of thrombocytopenia either [24]. Moreover, other researchers reported no differences in organ failure parameters including haematological, coagulological and cardiovascular ones [31].

The same team of researchers conducted a small randomized study (17 in SHC vs. 12 in WBC group) and recorded the death rate at 41 vs. 33% and survivors without disability of 18 vs. 33% in the SHC and WBC respectively [32]. However, the differences did not reach the level of statistical significance, which may be ascribed to a limited study group. Finally, the same authors analyzed certain neural and inflammatory biomarkers. The serum interleukin (IL)-1ß, IL-6, neuron-specific enolase (NSE), brain-specific creatine kinase (CK-BB), tumor necrosis factor-alpha (TNF-α), protein S100 levels, the urine S100B level and the urine lactate/creatinine (L/C) ratio were evaluated 6 and 72 hrs after birth. They did not observe significant differences between groups at assessed time points, neither did they find such differences when the changes between 6 and 72 h were determined in percentages [33].

Consistently with previous studies, also in our analysis no method has been proven superior. Although our research included the largest number of newborn infants investigated so far, we did not observe additional clinical benefit of WBC technique. Despite the lack of clinical advantages, the simplicity of usage of WBC (due to servo-control) should be emphasized.
The limitation of this study was a lack of randomization and a smaller sample of WBC group.

CONCLUSIONS
Both methods of therapeutic hypothermia are comparable. We did not find significant differences in short term outcomes and the risk of adverse effects between SHC vs. WBC in newborns with HIE. Our results require confirmation in the follow-up observation. The tendency to higher rate of PPHN in WBC group should be confirmed in subsequent studies.

Acknowledgements
We wish to express our thankfulness for the consent given by all the parents of the patients involved in the study. We would also like to thank all the co-operating regional hospitals.

Funding
Funding NN407547538 form Polish Ministry of Education and Science.

Clinical Trials.gov. ID NCT02499933.

The authors declare, that this is an original study as well it has not been previously published and has not been submitted for publication elsewhere while under consideration.

REFERENCES

